Nanobiotix Shares Drop 6.28% After an Exceptional Week with a 32.54% Increase

A Pause After Days of Strong Gains

The stock took a breather after benefiting from a renewed interest linked to several consecutive days of strong gains. In early October, the company unveiled encouraging clinical data for its drug candidate JNJ-1900 in treating esophageal cancer. The Phase 1 study, conducted by the MD Anderson Cancer Center, reported an objective response rate of 69% among thirteen patients with locally advanced esophageal adenocarcinoma, including six complete responses and three partial responses. The treatment was well tolerated, and the feasibility of the injection was confirmed. These results, presented at the annual congress of the American Society for Radiation Oncology, excited investors and led to a series of significant increases. On Wednesday, October 8, the stock surged 21.84% to 22.20 euros, extending an upward trend that began in mid-September. Following this, the investment bank Jefferies confirmed its buy recommendation by raising its price target to 21 euros, acknowledging that the stock still has potential for growth despite its already exceptional performance since the beginning of the year.

Friday's Session Marks a Pause in Momentum

However, Friday's session marked a halt in this upward momentum. The stock fell 6.28% to 22.40 euros, erasing some of the gains accumulated the previous day, while the CAC 40 index fell by 1.53%. Trading remained robust, with nearly 1.92% of the capital changing hands, a high level of liquidity indicating profit-taking after several sessions of uninterrupted gains. Over the past week, the stock still shows a gain of 32.54%, and over three months, the performance reaches 378.1%. For comparison, the CAC 40 has advanced 4.73% over a year, while Nanobiotix records a gain of 401.1% over the same period. This spectacular outperformance places the stock among the most dynamic on the Paris market, but also raises the question of a possible overheating in the short term. The stock is now just below its technical resistance at 23.90 euros, a level reached the previous day at the close, which now becomes a threshold to monitor to gauge the stock's ability to continue its rise.

Technical Analysis Highlights Unusual Overheating

Technical analysis highlights an unusual level of overheating. The relative strength index, which measures the intensity of price movements, is at 95, an extremely high level indicating a potential exhaustion of the buying momentum and suggesting a phase of consolidation or correction ahead. This signal is particularly significant as the stock is now far above its reference moving averages: the 50-day average is at 9.91 euros, and the 200-day average at 5.18 euros, levels significantly surpassed by the current price. Moreover, the Bollinger Bands, which frame price fluctuations based on volatility, indicate an upper bound at 22.94 euros, very close to the closing price. This configuration suggests that the stock is at the upper limit of its volatility channel, which could precede either a corrective pullback or a pause before a new impulse. The monthly volatility, measured at 34.87%, reflects the magnitude of recent movements and confirms that the stock is going through a phase of intense activity, typical of biotechnological values subject to major clinical catalysts.